Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by country, state, or city

Search by locations

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

6,656 studies for “New York”

Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial CancerRecruiting
NCT07198074Phase 3Updated Aug 21, 2026
Sponsor: National Cancer Institute (NCI)
Advanced Endometrial Carcinoma · Recurrent Endometrial Carcinoma
United States
A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast CancerRecruiting
NCT07287098Phase 2Updated Aug 21, 2026
Sponsor: Eli Lilly and Company
Breast Neoplasms
United States, Belgium, France, Germany, Ireland +2 more
Delaying the Onset of Nearsightedness Until Treatment (DONUT) Clinical TrialRecruiting
NCT07567040Phase 3Updated Aug 21, 2026
Sponsor: Ohio State University
Myopia
United States
A Safety, Reactogenicity and Immunogenicity Trial of RVX-sCPD9 Booster Intranasal COVID-19 VaccineNot Yet Recruiting
NCT07703475Phase 1Updated Aug 21, 2026
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
COVID -19
United States
EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)Recruiting
NCT06531824Phase 3Updated Aug 21, 2026
Sponsor: Boehringer Ingelheim
Kidney Disease, Chronic
United States, Argentina, Australia, Belgium, Brazil +15 more
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or OverweightRecruiting
NCT06937099Phase 3Updated Aug 21, 2026
Sponsor: Eli Lilly and Company
Crohn's Disease · Obesity or Overweight
United States, Austria, Belgium, Brazil, Bulgaria +17 more
A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)Recruiting
NCT07221474Phase 2Updated Aug 21, 2026
Sponsor: Merck Sharp & Dohme LLC
Squamous Non-small Cell Lung Cancer
United States, Argentina, Australia, Chile, France +6 more
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)Recruiting
NCT05519085Phase 3Updated Aug 21, 2026
Sponsor: Celgene
Relapsed or Refractory Multiple Myeloma
United States, Argentina, Australia, Austria, Belgium +24 more
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis SuppurativaActive Not Recruiting
NCT06468228Phase 3Updated Aug 21, 2026
Sponsor: AbbVie
Hidradenitis Suppurativa
United States, Argentina, Australia, Austria, Belgium +39 more
Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical CancerRecruiting
NCT07061977Phase 3Updated Aug 21, 2026
Sponsor: National Cancer Institute (NCI)
Locally Advanced Cervical Adenocarcinoma · Locally Advanced Cervical Adenosquamous Carcinoma · Locally Advanced Cervical Squamous Cell Carcinoma · Stage IIIA Cervical Cancer FIGO 2018
United States
An Efficacy and Safety Study of Clemizole HCl in Patients With Lennox-Gastaut SyndromeRecruiting
NCT05066217Phase 3Updated Aug 21, 2026
Sponsor: Epygenix
Lennox Gastaut Syndrome
United States, China, Italy, Poland, Romania +2 more
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)Recruiting
NCT07165028Phase 3Updated Aug 21, 2026
Sponsor: Eli Lilly and Company
Metabolic Dysfunction-Associated Steatotic Liver Disease
United States, Argentina, Australia, Austria, Belgium +29 more
Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)Recruiting
NCT07531095Phase 1Updated Aug 21, 2026
Sponsor: Amgen
Small Cell Lung Cancer
United States, Australia, Belgium, France, Germany +4 more
A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With CancerRecruiting
NCT07169851Phase 2Updated Aug 21, 2026
Sponsor: Eli Lilly and Company
Nausea · Vomiting · Drug-Related Side Effects and Adverse Reactions · Neoplasms
United States, Australia, China, France, Italy +5 more
Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal CancersActive Not Recruiting
NCT02466971Phase 3Updated Aug 21, 2026
Sponsor: National Cancer Institute (NCI)
Advanced Vaginal Adenocarcinoma · Advanced Vaginal Adenosquamous Carcinoma · Advanced Vaginal Squamous Cell Carcinoma · Cervical Adenocarcinoma
United States, Canada, Puerto Rico
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)Recruiting
NCT04419649Phase 2Updated Aug 21, 2026
Sponsor: Takeda
Myelodysplastic Syndromes · Cytopenia
United States, Australia, Czechia, France, Germany +3 more
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged LeukemiaRecruiting
NCT06317662Phase 2Updated Aug 21, 2026
Sponsor: National Cancer Institute (NCI)
Acute Leukemia of Ambiguous Lineage · B Acute Lymphoblastic Leukemia
United States, Puerto Rico
A Study to Evaluate Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With SchizophreniaTerminated
NCT05443724Phase 2Updated Aug 21, 2026
Sponsor: AbbVie
Schizophrenia
United States, Bulgaria, Hungary, Puerto Rico, Ukraine
Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or LymphomaActive Not Recruiting
NCT05602194Phase 3Updated Aug 21, 2026
Sponsor: Children's Oncology Group
B Acute Lymphoblastic Leukemia · B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 · B Acute Lymphoblastic Leukemia, BCR-ABL1-Like · Lymphoblastic Lymphoma
United States, Canada
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL StudyRecruiting
NCT04269902Phase 3Updated Aug 21, 2026
Sponsor: National Cancer Institute (NCI)
Chronic Lymphocytic Leukemia · Small Lymphocytic Lymphoma
United States, Canada
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver FibrosisRecruiting
NCT06632444Phase 3Updated Aug 21, 2026
Sponsor: Boehringer Ingelheim
Metabolic Dysfunction Associated Steatohepatitis (MASH) · Liver Fibrosis
United States, Argentina, Australia, Austria, Belgium +31 more
A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha ExpressionActive Not Recruiting
NCT06365853Phase 2Updated Aug 21, 2026
Sponsor: AbbVie
Recurrent Ovarian Cancer · Folate Receptor-Alpha Positive
United States, Australia, Belgium, Canada, France +2 more
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart FailureRecruiting
NCT06424288Phase 3Updated Aug 21, 2026
Sponsor: Boehringer Ingelheim
Heart Failure
United States, Argentina, Australia, Belgium, Brazil +25 more
A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)Recruiting
NCT07190248Phase 3Updated Aug 21, 2026
Sponsor: Merck Sharp & Dohme LLC
Non-small Cell Lung Cancer
United States, Argentina, Australia, Austria, Belgium +24 more
Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory LossCompleted
NCT02008357Phase 3Updated Aug 21, 2026
Sponsor: Eli Lilly and Company
Cognition Disorders
United States, Australia, Canada, Japan

6,656 studies found